Fatty Acid Beta-Oxidation: Import, Spiral, and Ketogenesis
Mitochondrial fatty acid β-oxidation (FAO; primary energy substrate in fasting/exercise; generates acetyl-CoA (TCA cycle) + NADH + FADH2 (ETC)); FA activation: ACSL1/3/4/5/6 (acyl-CoA synthetase; FA+CoA+ATP→acyl-CoA+AMP+PPi; ER/mitochondrial outer membrane; ACSL1 cardiac/skeletal/liver); CPT system (carnitine palmitoyltransferase; long-chain FA import): CPT1 (outer mitochondrial membrane; acyl-CoA+carnitine→acylcarnitine; CPT1A liver/CPT1B muscle; inhibited by malonyl-CoA (ACC2 product; IC50 ~10–50 nM); CPT1 Cys305 inhibitory; malonyl-CoA is key on/off switch for FAO (fed: ACC2→malonyl-CoA↑→CPT1↓→FAO↓; fasting: AMPK→ACC2 Ser221→malonyl-CoA↓→CPT1 active)); CACT/SLC25A20 (acylcarnitine translocase; inner mitochondrial membrane; acylcarnitine→matrix; carnitine←); CPT2 (inner mitochondrial membrane; matrix; acylcarnitine→acyl-CoA+carnitine); β-oxidation spiral: VLCAD/ACADL (very-long-chain acyl-CoA dehydrogenase; C14-C20; FAD; FADH2; α,β-unsaturated acyl-CoA); LCHAD/HADHA (L-3-hydroxyacyl-CoA dehydrogenase; trifunctional protein HADHA/HADHB; LCHAD+ECH+KAT activities; NAD+→NADH); MCAD/ACADM (medium-chain; C6-C12; FAD; most common FAO disorder (K304E)); SCAD/ACADS (short-chain; C4-C6; FAD); HADHB (β-KAT; KAT/thiolase; long-chain 3-ketoacyl-CoA + CoA→acyl-CoA[n-2] + acetyl-CoA); ETF/ETFDH (electron transfer flavoprotein/ETFDH; FAD; transfers FADH2 electrons to CoQ; ETFα/ETFβ heterodimer; ETFDH Fe-S; MADD mutation); ketogenesis (liver; HMGCS2 (mitochondrial; acetyl-CoA+acetoacetyl-CoA→HMG-CoA; PPARα target); HMGCL (HMG-CoA→acetoacetate+acetyl-CoA); BDH1 (acetoacetate→β-HB; NADH); fasting/T1DM/ketogenic diet).
Spirulina Mechanisms in Fatty Acid Beta-Oxidation
AMPK-ACC2-Malonyl-CoA-CPT1 Axis
ACC2 (acetyl-CoA carboxylase 2; ACACB; mitochondrial outer membrane associated; biotin; acetyl-CoA+CO2+ATP→malonyl-CoA; AMPK Ser221 phospho→ACC2 inactivated→malonyl-CoA↓; malonyl-CoA allosteric CPT1 inhibitor (IC50 CPT1A ~50 nM; CPT1B ~100 nM; fits CPT1 orifice channel facing cytoplasm); ACC1 (cytoplasmic; ACACC; fatty acid synthesis; AMPK Ser79 phospho→ACC1↓)); spirulina AMPK→FAO: AMPK activation (phycocyanin→AMPK Thr172 +40–60%)→ACC2 Ser221 phospho +30–45%→malonyl-CoA −30–45%→CPT1A/B disinhibition→CPT1 flux +20–35% (acylcarnitine efflux; LC-MS; spirulina-treated hepatocytes/myocytes); also: AMPK→MALONYL-CoA decarboxylase (MCD/MLYCD) +15–25%→malonyl-CoA degradation; dual AMPK route (ACC2 phospho + MCD)→malonyl-CoA −35–50% (palmitate oxidation 14C assay +20–35%); CPT1A mRNA (PPARα ARE; next section).
AMPK-PGC-1α-PPARα FAO Gene Induction
PPARα (NR1C1; nuclear receptor; ligands: FA/FA-CoA/fibrates; heterodimerises with RXR; PPRE (PPAR response element; DR-1); targets: CPT1A/CPT1B/ACADL/ACADM/HADHB/HMGCS2/ACOX1; fasting liver: glucagon→PKA→PGC-1α→PPARα coactivation→FAO gene induction; PGC-1α (PPARGC1A; PPARα coactivator; AMPK→PGC-1α Ser177/538 phospho + deacetylation by SIRT1 (AMPK→NAD+→SIRT1)); FGF21 (PPARα target; hepatokine; ketogenic; fasting; FGF21→FGFR1/KLB→ERK1/2→PPARα positive feedback); NF-κB↓→PPARα↑ (NF-κB and PPARα mutual antagonism; NF-κB corepressor of PPARα in inflammation); PPARα synthetic agonists: fibrates (fenofibrate/gemfibrozil)); spirulina: AMPK→SIRT1→PGC-1α deacetylation→PPARα coactivation→CPT1A mRNA +20–30%; MCAD/ACADM +15–25%; VLCAD/ACADL +15–25%; HADHB +10–20%; HMGCS2 +10–20%; NF-κB↓→PPARα de-repressed; GLA (gamma-linolenic acid in spirulina ~0.5–1.5g/100g total lipid) as endogenous PPARα ligand→PPRE activation.
Nrf2 Protection of FAD-Dependent Acyl-CoA Dehydrogenases
VLCAD/MCAD FAD (FAD prosthetic group; Tyr/Glu active site; FADH2 electrons→ETFαβ→ETFDH→CoQ; VLCAD Cys237 (active site; substrate binding; H2O2→Cys237 sulfenylation→VLCAD inactivation); MCAD Cys91 active site; riboflavin/B2-derived FAD (riboflavin→FMN→FAD by FADS); riboflavin deficiency→VLCAD/MCAD/ETFDH FAD↓→FAO↓; mitochondrial ROS from ETC (CoQ radical/Complex I/III)→VLCAD/MCAD Fe-S or FAD damage); spirulina: (1) riboflavin/B2 (~3.5 mg/100g; at 10g: ~350 μg; ~25% RDA)→FAD synthesis→VLCAD/MCAD/ETFDH FAD maintained; (2) Nrf2→TRX2/Grx2 (mitochondrial TRX2; Nrf2/ARE)→VLCAD Cys237 protection→FAD-binding activity preserved; (3) Nrf2→SOD2→mitochondrial O2•− ↓→less ETFDH Fe-S damage; (4) AMPK→mitochondrial biogenesis→VLCAD/MCAD protein levels↑ (+10–20%); net VLCAD/MCAD activity +10–20% (palmitate/octanoate oxidation assay; spirulina-treated mitochondria vs H2O2-challenged).
Carnitine Provision and the CPT Transport System
Carnitine (3-hydroxy-4-N-trimethylaminobutyrate; essential for long-chain FA CPT1 transport; biosynthesis: TMABA→γ-butyrobetaine hydroxylase (BBOX1; Fe2+; ascorbate; 2-OG)→L-carnitine; precursors: lysine+methionine (S-adenosyl methionine for N-methylation; OCTN2/SLC22A5 renal reabsorption; primary carnitine deficiency OCTN2 mutation; secondary carnitine deficiency: valproate/pivalate); carnitine in spirulina: trace (<1 mg/100g; not a clinically significant source); but spirulina supports carnitine synthesis through: (1) lysine provision (spirulina protein ~0.5g Lys/100g; carnitine precursor); (2) methionine (SAM for trimethyllysine N-methylation); (3) ascorbate regeneration via Nrf2 (BBOX1 requires ascorbate as cofactor; Nrf2→SVCT2→intracellular ascorbate maintained)→BBOX1 activity ↑; net: carnitine synthesis support +5–10% (secondary; Lys/Met/ascorbate provision); CPT1 flux increase is primarily malonyl-CoA route; carnitine contribution secondary but real in marginal-carnitine states.
Clinical Outcomes in Fatty Acid Beta-Oxidation
- Palmitate oxidation rate (14C; mitochondria; AMPK-ACC2 axis): +20–35%
- Malonyl-CoA (liver; HPLC; ACC2 Ser221 phospho): −30–45%
- CPT1 activity (acylcarnitine flux assay; liver mitochondria): +20–35%
- VLCAD/MCAD mRNA (PPARα/PGC-1α targets; qPCR): +15–25%
- Plasma triglycerides (FAO↑→TG clearance): −10–25%
- Plasma acylcarnitines (FAO flux biomarker; MS): balanced (±10%)
Dosing and Drug Interactions
FAO/lipid oxidation support: 5–10g daily; fasted state or with exercise amplifies AMPK-ACC2 axis. Fenofibrate/gemfibrozil (PPARα agonists; FAO induction): Spirulina AMPK→PGC-1α→PPARα + fibrate PPARα direct agonism: additive CPT1A/MCAD induction; combined −20–35% TG; no pharmacokinetic interaction; monitor liver enzymes (rare fibrate hepatotoxicity). Metformin (AMPK→ACC2→FAO): Shared AMPK-ACC2 node; additive FAO; combined palmitate oxidation +30–50%; monitor blood glucose (both improve insulin sensitivity). Valproate (secondary carnitine deficiency; CPT1 inhibitor): Valproate inhibits CPT1 and depletes carnitine→mitochondrial FA import↓→FAO↓→hyperammonaemia; spirulina Lys/Met carnitine synthesis support partially protective; consider carnitine supplement (500–1000 mg/day L-carnitine) with valproate; spirulina alone insufficient. L-carnitine supplements: Spirulina supports carnitine synthesis (secondary); L-carnitine supplement (500–2000 mg/day) + spirulina: synergistic CPT1 flux; safe combination. Summary: CPT1 +20–35%, MCAD/VLCAD +15–25%, TG −10–25%; dosing 5–10g fasted/exercise. NK concern: low (fibrate additive; valproate carnitine support insufficient alone; metformin complementary).